Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.45 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480282 | 1.00 | L3MBTL1 (0.49) | L3MBTL1KDM4EENPP2NAMPTALDH1A1 | |
| SCHEMBL5479562 | 0.90 | L3MBTL1 (0.50) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5479555 | 0.90 | L3MBTL1 (0.50) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5485005 | 0.88 | ALDH1A1 (0.54) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5484998 | 0.88 | ALDH1A1 (0.54) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5483056 | 0.88 | LMNA (0.55) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5483061 | 0.88 | LMNA (0.55) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5486556 | 0.85 | L3MBTL1 (0.69) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5486563 | 0.85 | L3MBTL1 (0.69) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 | |
| SCHEMBL5486990 | 0.84 | L3MBTL1 (0.53) | L3MBTL1KDM4EENPP2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | L3MBTL1 4137/4885KDM4E 1679/4885ENPP2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.